This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. [...] Details of the critical appraisal of the included studies are presented in Appendix 3. Summary of Findings The main findings of the included studies are presented in Appendix 4. What is the clinical effectiveness and safety of 3-month paliperidone palmitate injectable formulation for the treatment of adults with schizophrenia? [...] Non-inferiority of PP3M would be concluded if the lower limit of the 2-sided 95% CI of the difference in relapse-free rates between the two formulations was larger than the pre specified margin -15%. [...] The lower bound of the 95% CI between the two formulations in the percentage of patients who remained relapse-free (-2.7%) was found to be larger than the pre-specified non- inferiority margin. [...] SUMMARY WITH CRITICAL APPRAISALThree-month Injectable Paliperidone Palmitate for Schizophrenia 6 What are the evidence-based guidelines associated with the use of 3-month paliperidone palmitate injectable formulation for the treatment of adults with schizophrenia?